查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1750738

痛風藥物市場規模、佔有率、趨勢分析報告：依藥物類別、疾病狀況、通路、地區、細分預測，2025-2030 年

Gout Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents), By Disease Condition, By Distribution Channel (Hospital Pharmacy), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

痛風藥物市場的成長與趨勢：

根據 Grand View Research 的最新報告，預計到 2030 年全球痛風藥物市場規模將達到 41.3 億美元。

預計2025年至2030年，該市場的複合年成長率將達到6.45%。市場的成長可以歸因於全球疾病負擔的增加、政府和私人組織在民眾中傳播疾病意識的努力，以及該領域新治療方法的最新進展。此外，臨床研發線藥物數量的增加也提供了豐厚的市場成長機會。

痛風的盛行率在全球範圍內不斷上升，這是推動市場成長的關鍵因素。例如，根據愛思唯爾的一篇論文，2021年澳洲痛風的盛行率為1.5%至2.9%。同樣，加拿大和英國報告稱，2021年痛風病例增幅分別約為4%和2.33%。老年人口的成長、不良飲食習慣（例如飲酒和攝取果糖）、久坐不動的生活方式以及腎臟疾病、心血管疾病和糖尿病等併發症的增多，進一步加劇了痛風的高盛行率。

強勁的臨床試驗管線和前景看好的新療法上市預計將在預測期內推動市場成長。目前，江蘇恆瑞醫藥股份有限公司的SHR4,640等候選藥物正處於治療痛風的3期臨床試驗階段。同樣，2023年3月，Selecta Biosciences, Inc.宣布其SEL-212的3期DISSOLVE I & II安慰劑對照隨機臨床試驗取得了積極結果。 SEL-212適用於治療慢性難治性痛風。

主要企業正在採取合作、併購、協議和金融投資等策略性舉措，以推動市場成長。例如，2021年6月，Horizo​​​​n Therapeutics plc與Arrowhead Pharmaceuticals合作開發了一種RNAi治療劑，作為治療未受控制的痛風的潛在藥物。 2022年7月，該公司獲得FDA擴大核准，將Krystexxa用於治療未控制的痛風患者。該藥物與免疫療法和化療藥物胺基甲基葉酸合併使用。

此外，Horizo​​​​n 於 2023 年 3 月啟動了全國腎臟月宣傳活動「痛風除草」（Weed it G'out）。宣傳活動以鮮花和野草為主題，展現尿酸與其對腎臟的影響之間的關聯。該宣傳活動旨在提高人們對痛風的認知，鼓勵人們認真對待痛風並諮詢專家。

痛風治療藥物市場報告重點

  • 由於處方率高、成本低、市場佔有率高，非類固醇抗發炎藥領域在 2024 年佔據了最大的市場佔有率。
  • 根據疾病情況，急性病領域在 2024 年佔總市場佔有率的 65.77%，因為與慢性病相比，急性病患者數量更多。
  • 到 2024 年，零售藥局將佔據該領域最高的佔有率。然而，預計線上藥局將成為預測期內成長最快的領域。
  • 由於痛風患者數量不斷增加、個人對疾病治療的認知程度較高以及醫療保健服務便利性等因素，北美將在 2024 年主導全球市場。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 痛風藥物市場變因、趨勢與範圍

  • 市場展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 痛風治療市場分析工具
    • 產業分析—波特五力分析
    • PESTEL分析
    • 定價分析
    • 管道分析

第4章 痛風治療市場：藥物類別估計與趨勢分析

  • 全球痛風藥物市場：藥物類別儀表板
  • 全球痛風藥物市場：藥物類別變化分析
  • 全球痛風藥物市場（按藥物類別和收益）
  • NSAIDs
  • 皮質類固醇
  • 秋水仙鹼
  • 降尿酸藥
  • 其他

第5章痛風治療市場：疾病狀況評估及趨勢分析

  • 全球痛風藥物市場：疾病儀表板
  • 全球痛風治療市場：病理狀態變化分析
  • 全球痛風治療市場（按疾病狀況和收益）
  • 急性痛風
  • 慢性痛風
  • 慢性痛風市場估計與預測（2018-2030）

第6章痛風治療市場：通路評估及趨勢分析

  • 全球痛風藥物市場：分銷通路儀表板
  • 全球痛風藥物市場：流通通路變化分析
  • 全球痛風藥物市場（按分銷管道和收益）
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 7 章痛風藥物市場：按藥物類別、疾病狀態和通路進行區域估計和趨勢分析。

  • 區域儀表板
  • 市場規模、預測趨勢分析，2018 年至 2030 年：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • Key customers
    • Key company market share analysis, 2024
    • Takeda Pharmaceutical Company Limited
    • Novartis Pharmaceuticals Corporation
    • Regeneron Pharmaceuticals Inc.
    • Merck &Co., Inc.
    • AstraZeneca
    • Arrowhead Pharmaceuticals Inc.
    • AstraZeneca
    • Teijin Pharma Ltd.
    • GSK plc.
    • Zydus Group
Product Code: GVR-1-68038-717-9

Gout Therapeutics Market Growth & Trends:

The global gout therapeutics market size is anticipated to reach USD 4.13 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 6.45% from 2025 to 2030. The growth of the market is attributed to the global rise in disease burden, initiatives undertaken by government and private organizations to spread awareness among people, and the recent development of novel therapies in the space. Furthermore, the growing number of clinical pipeline drugs offers lucrative market growth opportunities.

The world is witnessing an increasing prevalence of gout, which is the key factor driving market growth. For instance, according to an Elsevier article, in 2021, Australia reported prevalence rates between 1.5% to 2.9% for gout. Similarly, in 2021, Canada and UK reported approximately 4% and 2.33% rise in disease cases respectively. High prevalence is further supported by the high geriatric population, improper diets such as consumption of alcohol and fructose, increasing sedentary lifestyle, and comorbidities like renal impairment, cardiovascular diseases, and diabetes.

The robust clinical trial pipeline and the anticipated launch of new therapeutics are expected to boost market growth over the forecast period. Presently, drug candidates like Jiangsu HengRui Medicine Co., Ltd.'s SHR4640 are in phase 3 clinical investigation for the treatment of gout. Similarly, in March 2023, Selecta Biosciences, Inc announced positive results for the Phase 3 DISSOLVE I & II placebo-controlled randomized clinical trials of SEL-212. SEL-212 is indicated for chronic refractory gout.

Key players are undertaking strategic initiatives such as collaborations, mergers and acquisitions, agreements, and financial investments, driving market growth. For instance, in June 2021, Horizon Therapeutics plc collaborated with Arrowhead Pharmaceuticals to develop RNAi therapeutic, a potential treatment for uncontrolled gout. In July 2022, the company received expanded FDA approval for Krystexxa for patients with uncontrolled gout. It is used in combination with immunotherapy and chemotherapy drug, methotrexate.

Additionally, in March 2023, Horizon organized a campaign, "Weed it G'out" for National Kidney Month. The campaign uses flowers and weeds to depict the correlation to the effect of uric acid on kidneys. The campaign aims to create awareness and urge people to take gout seriously and consult a specialist.

Gout Therapeutics Market Report Highlights:

  • NSAIDs segment accounted for the largest share of the market in 2024 due to the high prescription rate, low cost, and strong presence in the market.
  • Based on disease condition, the acute condition segment held 65.77% of the total market share in 2024, owing to a high patient pool compared to the chronic condition
  • In 2024, retail pharmacy held the highest segment share in the space. However, online pharmacy is expected to be the fastest-growing segment over the forecast period
  • North America dominated the global market in 2024 owing to factors such as increased gout cases, high awareness among individuals for disease treatment, and better healthcare access in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Disease Condition
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class outlook
    • 2.2.2. Disease Condition outlook
    • 2.2.3. Distribution Channel outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Gout Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Gout Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis
      • 3.3.4.1. Phase 1
      • 3.3.4.2. Phase 2
      • 3.3.4.3. Phase 2

Chapter 4. Gout Therapeutics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Global Gout Therapeutics Market: Drug Class Dashboard
  • 4.2. Global Gout Therapeutics Market: Drug Class Movement Analysis
  • 4.3. Global Gout Therapeutics Market by Drug Class, Revenue
  • 4.4. NSAIDs
    • 4.4.1. NSAIDs market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Corticosteroids
    • 4.5.1. Corticosteroids market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Colchicine
    • 4.6.1. Colchicine market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Urate-Lowering Agents
    • 4.7.1. Urate-Lowering Agents market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Gout Therapeutics Market: Disease Condition Estimates & Trend Analysis

  • 5.1. Global Gout Therapeutics Market: Disease Condition Dashboard
  • 5.2. Global Gout Therapeutics Market: Disease Condition Movement Analysis
  • 5.3. Global Gout Therapeutics Market by Disease Condition, Revenue
  • 5.4. Acute Gout
    • 5.4.1. Acute Gout market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Chronic Gout
  • 5.6. Chronic Gout market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Gout Therapeutics Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global Gout Therapeutics Market: Distribution Channel Dashboard
  • 6.2. Global Gout Therapeutics Market: Distribution Channel Movement Analysis
  • 6.3. Global Gout Therapeutics Market by Distribution Channel, Revenue
  • 6.4. Hospital Pharmacy
    • 6.4.1. Hospital Pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Retail Pharmacy
    • 6.5.1. Retail Pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Online Pharmacy
    • 6.6.1. Online Pharmacy market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Gout Therapeutics Market: Regional Estimates & Trend Analysis by Drug Class, Disease Condition, and Distribution Channel.

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Takeda Pharmaceutical Company Limited
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Novartis Pharmaceuticals Corporation
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Regeneron Pharmaceuticals Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Merck & Co., Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. AstraZeneca
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Arrowhead Pharmaceuticals Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. AstraZeneca
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Teijin Pharma Ltd.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. GSK plc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Zydus Group
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 3 North America Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 4 North America Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 5 U.S. Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 6 U.S. Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 7 U.S. Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 Canada Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 9 Canada Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 10 Canada Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 Mexico Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 12 Mexico Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 13 Mexico Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Europe Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 15 Europe Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 16 Europe Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Germany Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 18 Germany Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 19 Germany Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 UK Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 21 UK Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 22 UK Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 France Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 24 France Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 25 France Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Italy Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 27 Italy Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 28 Italy Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 Spain Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 30 Spain Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 31 Spain Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Denmark Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 33 Denmark Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 34 Denmark Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Sweden Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 36 Sweden Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 37 Sweden Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Norway Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 39 Norway Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 40 Norway Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 China Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 45 China Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 46 China Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Japan Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 48 Japan Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 49 Japan Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 50 India Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 51 India Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 52 India Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 South Korea Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 54 South Korea Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 55 South Korea Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 Australia Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 57 Australia Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 58 Australia Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 Thailand Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 60 Thailand Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 61 Thailand Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 Latin America Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 63 Latin America Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 64 Latin America Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Brazil Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 66 Brazil Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 67 Brazil Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 68 Argentina Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 69 Argentina Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 70 Argentina Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 71 MEA Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 72 MEA Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 73 MEA Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 74 South Africa Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 75 South Africa Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 76 South Africa Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 77 Saudi Arabia Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 78 Saudi Arabia Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 79 Saudi Arabia Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 80 UAE Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 81 UAE Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 82 UAE Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 83 Kuwait Gout Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 84 Kuwait Gout Therapeutics Market, by Disease Condition, 2018 - 2030 (USD Million)
  • Table 85 Kuwait Gout Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Gout Therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product and Distribution Channel segment snapshot
  • Fig. 10 Application segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Pharmaceutical market (USD Billion)
  • Fig. 13 Market dynamics
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Gout Therapeutics market: Drug Class outlook and key takeaways
  • Fig. 17 Gout Therapeutics market: Drug Class movement analysis
  • Fig. 18 Gout Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 NSAIDs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Corticosteroids market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Colchicine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Urate-Lowering Agents market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Gout Therapeutics market: Disease Condition outlook and key takeaways
  • Fig. 25 Gout Therapeutics market: Disease Condition movement analysis
  • Fig. 26 Acute Gout market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Chronic Gout market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Gout Therapeutics market: Distribution Channel and key takeaways
  • Fig. 29 Gout Therapeutics market: Distribution Channel movement analysis
  • Fig. 30 Hospital Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Retail Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Online Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Gout Therapeutics market revenue, by region, 2024 & 2030, (USD million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Key country dynamics
  • Fig. 37 Target disease prevalence
  • Fig. 38 U.S. gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 Target disease prevalence
  • Fig. 41 Canada gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Target disease prevalence
  • Fig. 44 Mexico gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Target disease prevalence
  • Fig. 47 Europe gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Target disease prevalence
  • Fig. 50 UK gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Target disease prevalence
  • Fig. 53 Germany gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Target disease prevalence
  • Fig. 56 France gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Target disease prevalence
  • Fig. 59 Spain gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Target disease prevalence
  • Fig. 62 Italy gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Target disease prevalence
  • Fig. 65 Denmark gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Target disease prevalence
  • Fig. 68 Sweden gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Target disease prevalence
  • Fig. 71 Norway gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Rest of Europe gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Asia Pacific gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Target disease prevalence
  • Fig. 76 Japan gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Target disease prevalence
  • Fig. 79 China gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Target disease prevalence
  • Fig. 82 India gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Target disease prevalence
  • Fig. 85 Australia gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Thailand gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 South Korea gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Rest of Asia Pacific gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Latin America gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Target disease prevalence
  • Fig. 94 Brazil gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Target disease prevalence
  • Fig. 97 Argentina gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Rest of Latin America gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 MEA gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Key country dynamics
  • Fig. 101 Target disease prevalence
  • Fig. 102 South Africa gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Key country dynamics
  • Fig. 104 Target disease prevalence
  • Fig. 105 Saudi Arabia gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Key country dynamics
  • Fig. 107 Target disease prevalence
  • Fig. 108 UAE gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 Target disease prevalence
  • Fig. 111 Kuwait gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 Rest of MEA gout therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)